Akebia Therapeutics (AKBA) Operating Leases: 2019-2025
Historic Operating Leases for Akebia Therapeutics (AKBA) over the last 7 years, with Sep 2025 value amounting to $4.9 million.
- Akebia Therapeutics' Operating Leases fell 51.73% to $4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.9 million, marking a year-over-year decrease of 51.73%. This contributed to the annual value of $3.5 million for FY2024, which is 60.36% down from last year.
- Akebia Therapeutics' Operating Leases amounted to $4.9 million in Q3 2025, which was down 21.66% from $6.3 million recorded in Q2 2025.
- Over the past 5 years, Akebia Therapeutics' Operating Leases peaked at $37.7 million during Q1 2022, and registered a low of $3.5 million during Q4 2024.
- Its 3-year average for Operating Leases is $11.8 million, with a median of $10.2 million in 2024.
- Its Operating Leases has fluctuated over the past 5 years, first skyrocketed by 36.89% in 2021, then plummeted by 69.11% in 2023.
- Quarterly analysis of 5 years shows Akebia Therapeutics' Operating Leases stood at $33.7 million in 2021, then decreased by 14.07% to $29.0 million in 2022, then slumped by 69.11% to $8.9 million in 2023, then crashed by 60.36% to $3.5 million in 2024, then slumped by 51.73% to $4.9 million in 2025.
- Its Operating Leases stands at $4.9 million for Q3 2025, versus $6.3 million for Q2 2025 and $7.6 million for Q1 2025.